礼来美股盘前涨2.6%
Mei Ri Jing Ji Xin Wen·2026-02-23 09:55
Group 1 - The core point of the article is that Eli Lilly's stock rose by 2.6% in pre-market trading due to the news that Novo Nordisk's weight loss drug performed worse than Eli Lilly's in the CagriSema trial [1] Group 2 - Eli Lilly's positive market reaction indicates investor confidence in its drug performance compared to competitors [1] - The comparison of drug efficacy between Eli Lilly and Novo Nordisk highlights the competitive landscape in the weight loss medication market [1]